Compagnie Lombard Odier SCmA’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,920	Closed	-$506K	–	661
2022 Q2	$506K	Sell	7,920 -5,280	-40%	-$335K	0.01%	200
2022 Q1	$855K	Hold	13,200	–	–	0.02%	165
2021 Q4	$878K	Buy	+13,200	New	+$837K	0.02%	190
2016 Q3	–	Sell	-450	Closed	-$22K	–	915
2016 Q2	$22K	Hold	450	–	–	﹤0.01%	772
2016 Q1	$21K	Sell	450 -9,804	-96%	-$459K	﹤0.01%	824
2015 Q4	$552K	Hold	10,254	–	–	0.02%	300
2015 Q3	$506K	Buy	10,254 +810	+9%	+$46.4K	0.02%	272
2015 Q2	$550K	Hold	9,444	–	–	0.02%	291
2015 Q1	$543K	Sell	9,444 -9,000	-49%	-$492K	0.02%	302
2014 Q4	$930K	Buy	+18,444	New	+$899K	0.04%	204

Other funds holding IHE

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Compagnie Lombard Odier SCmA's IHE Position: Q3 2022 in Review

Compagnie Lombard Odier SCmA sold out of iShares US Pharmaceuticals ETF (IHE) in Q3 2022, closing a stake of 7,920 shares — an estimated $506K sold.

Compagnie Lombard Odier SCmA first reported a position in IHE in Q4 2014 and held it in 10 quarters. The position peaked at $930K in Q4 2014. 113 funds tracked by Wall St. Rank hold IHE as of Q3 2022.

Compagnie Lombard Odier SCmA reported no remaining iShares US Pharmaceuticals ETF position as of Q3 2022 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 7,920 iShares US Pharmaceuticals ETF shares in Q3 2022, an estimated $506K.
Compagnie Lombard Odier SCmA first reported a position in iShares US Pharmaceuticals ETF in Q4 2014 and held it in 10 quarters.
Compagnie Lombard Odier SCmA's iShares US Pharmaceuticals ETF position peaked at $930K in Q4 2014.
113 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2022, filed 9 Nov 2022.